Clinical Trial Update: Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies [Phase 2]

View source ↗

Summary

Phase 2 study evaluating a triple regimen of vorinostat, tacrolimus, and methotrexate to prevent graft-versus-host disease after allogeneic stem cell transplant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Burkitt Lymphoma
• Chronic Myeloid Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Hodgkin Lymphoma
• Myelodysplastic Syndrome
• Non-hodgkin Lymphoma

Drugs mentioned

• METHOTREXATE (METHOTREXATE)
• Tacrolimus (Tacrolimus)
• Vorinostat (vorinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Status: COMPLETED | Results posted: 2015-11-13